Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
G. Frasci(Radiation Oncology Institute), Mario De Lena(Radiation Oncology Institute), G.P. Nicolella(Radiation Oncology Institute), Annunziato Iannelli(Radiation Oncology Institute), Francovito Piantedosi(Ospedale Monaldi), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), B. Massidda(Policlinico Universitario di Catania), Andrea Bianco(Keele University), Giuseppe De Cataldis(Radiation Oncology Institute), Pasquale Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M Belli(Radiation Oncology Institute), Giuseppe Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Panza(Radiation Oncology Institute), Vito Lorusso(Istituto Tumori Bari)
Cited by 452
Related Papers
Polymorphism at the Glutathione <i>S</i> -transferase GSTP1 Locus: A New Marker for Bronchial Hyperresponsiveness and Asthma
|American Journal of Respiratory and Critical Care Medicine|2000|263
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
|Lung Cancer|2019|158
Adiponectin as Link Factor between Adipose Tissue and Cancer
|International Journal of Molecular Sciences|2019|138
Lapatinib in breast cancer
|Annals of Oncology|2007|129